COEP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.25%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Coeptis Therapeutics Insider Trading History Chart

Coeptis Therapeutics Share Price & Price History

^$9.40

+0.30 (1.20%)

As of 04/11/2025 04:59 PM ET

Days: 30 | 90 | 365

Coeptis Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2024	Tara Desilva	Director	Buy	113	$11.60	$1,310.80	1,613
1/10/2024	Brian Cogley	CFO	Buy	250	$13.40	$3,350.00	1,500
1/8/2024	David Mehalick	CEO	Buy	1,000	$13.20	$13,200.00	139,130
1/5/2024	Daniel Alexander Yerace	VP	Buy	542	$13.80	$7,479.60	53,572
1/5/2024	David Mehalick	CEO	Buy	252	$13.80	$3,477.60	138,130
1/5/2024	Gene Salkind	Director	Buy	580	$13.80	$8,004.00	14,202
8/29/2023	Gene Salkind	Director	Buy	200	$20.20	$4,040.00	202
8/25/2023	Gene Salkind	Director	Buy	1,431	$18.20	$26,044.20	1,431
8/23/2023	Chris Calise	Director	Buy	579	$18.80	$10,885.20	73,244

See Full Table

SEC Filings (Institutional Ownership Changes) for Coeptis Therapeutics (NASDAQ:COEP)

13.88% of Coeptis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Coeptis Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2024	Armistice Capital LLC	3,520,000	$2.76M	0.0%	+59.1%	10.320%
11/15/2023	Armistice Capital LLC	2,212,000	$2.57M	0.0%	-5.1%	8.799%
8/15/2023	Ionic Capital Management LLC	45,000	$70K	0.0%	N/A	0.209%
7/21/2023	Creative Planning	645,103	$1M	0.0%	N/A	2.995%
5/12/2023	Antara Capital LP	45,000	$64K	0.0%	N/A	0.220%
2/14/2023	Susquehanna International Group LLP	16,341	$25K	0.0%	N/A	0.319%
2/10/2023	Creative Planning	645,103	$0.99M	0.0%	N/A	12.600%
2/10/2023	HRT Financial LP	172,635	$0.27M	0.0%	N/A	3.372%
2/8/2023	Cambridge Investment Research Advisors Inc.	31,670	$48K	0.0%	N/A	0.619%
2/6/2023	West Chester Capital Advisors Inc.	2,863,382	$4.39M	8.7%	N/A	55.925%

Data available starting January 2016

See Full Table

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Today's Range

Now: $9.40

$9.40

$9.65

50 Day Range

MA: $10.39

$8.50

$13.20

52 Week Range

Now: $9.40

$2.31

$13.70

Volume

12,398 shs

Average Volume

112,414 shs

Market Capitalization

$31.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Coeptis Therapeutics?: Coeptis Therapeutics' top insider investors include:
David Mehalick (CEO)
Chris Calise (Director)
Daniel Alexander Yerace (VP)
Gene Salkind (Director)
Tara Desilva (Director)
Brian Cogley (CFO)
Learn More about top insider investors at Coeptis Therapeutics.